Lantus up last week, but new scrips fall

In the wake of new safety concerns about the drug, total U.S. prescription volume for the Sanofi-Aventis diabetes drug Lantus inched up 2 percent last week versus the week before, but new prescriptions were down 3.8 percent, according to a drug-data provider. Report